Evidence map›Paper›PMID 36230912›Full record

ArticleCells2022

Single-Cell Gene Expression Analysis Revealed Immune Cell Signatures of Delta COVID-19.

Abusaid M Shaymardanov, Olga A Antonova, Anastasia D Sokol, Kseniia A Deinichenko, Polina G Kazakova, Mikhail M Milovanov, Alexander V Zakubansky, Alexandra I Akinshina, Anastasia V Tsypkina, Svetlana V Romanova and 10 more

Abstract read
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Abusaid M ShaymardanovCentre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.ORCID 0000-0003-0395-2528
Olga A AntonovaCentre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
Anastasia D SokolCentre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
Kseniia A DeinichenkoCentre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
Polina G KazakovaCentre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.ORCID 0000-0002-8966-4158
Mikhail M MilovanovCentre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
Alexander V ZakubanskyCentre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
Alexandra I AkinshinaCentre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
Anastasia V TsypkinaCentre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
Svetlana V RomanovaCentre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
Vladimir E MuhinCentre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.ORCID 0000-0001-8973-7890
Sergey I MitrofanovCentre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.ORCID 0000-0003-0358-0568
Vladimir S YudinCentre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.ORCID 0000-0002-9199-6258
Sergey M YudinCentre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
Antonida V MakhotenkoCentre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
Anton A KeskinovCentre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
Sergey A KraevoyCentre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
Ekaterina A SnigirCentre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
Dmitry V SvetlichnyyCentre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.ORCID 0000-0002-3776-9871
Veronika I SkvortsovaThe Federal Medical Biological Agency (FMBA of Russia), 30 Volokolamskoe sh., Moscow 125310, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19) is accompanied by a cytokine storm with the release of many proinflammatory factors and development of respiratory syndrome. Several SARS-CoV-2 lineages have been identified, and the Delta variant (B.1.617), linked with high mortality risk, has become dominant in many countries. Understanding the immune responses associated with COVID-19 lineages may therefore aid the development of therapeutic and diagnostic strategies. Multiple single-cell gene expression studies revealed innate and adaptive immunological factors and pathways correlated with COVID-19 severity. Additional investigations covering host-pathogen response characteristics for infection caused by different lineages are required. Here, we performed single-cell transcriptome profiling of blood mononuclear cells from the individuals with different severity of the COVID-19 and virus lineages to uncover variant specific molecular factors associated with immunity. We identified significant changes in lymphoid and myeloid cells. Our study highlights that an abundant population of monocytes with specific gene expression signatures accompanies Delta lineage of SARS-CoV-2 and contributes to COVID-19 pathogenesis inferring immune components for targeted therapy.

Indexed as

COVID-19Gene ExpressionHumansImmunologic FactorsSARS-CoV-2Immunologic FactorsCOVID-19immune systemmonocytessingle-celltranscriptome

Identifiers

PMID36230912
PMCPMC9563974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.